Phoenix News APP learned that Bocom Intl released a research report stating that with the inclusion of national procurement, the reduction in cochlear implant prices is expected to increase market demand, creating market share substitution space for domestic brands. The bank believes that in the short term, the mainland pharmaceutical sector still has further room for recovery, and focuses on recommending Simcere Pharma (02096), Hutchmed (China) (00013), Kono-A (02162), and Akeso (09926), with innovative drug symbols that have abundant short-term catalysts, high profit growth or clear profit and loss balance time, and valuation with significant repair elasticity.

Furthermore, on September 29, the National Medical Consumables Joint Procurement Platform issued a notice on the centralized maintenance work of cochlear and peripheral intervention medical consumables, officially starting this year's national procurement work. Currently, Sichuan, Shanxi, and other places have initiated the historical procurement data filling work. On September 26, Hebei Medical Insurance Bureau issued a notice regarding the continued implementation of the national medical insurance negotiation drug landing work, clarifying that apart from antimicrobial drugs, the number of negotiable drug varieties is not restricted by assessment. Currently, Jiangsu, Shaanxi, Jiangxi, and other places have relaxed the restrictions on the quantity of national negotiation drugs to varying degrees.